ライフサイエンスコーパス: chronic viral hepatitis

1 ced hepatocellular carcinoma with or without chronic viral hepatitis.

2 nsible for the most severe form of acute and chronic viral hepatitis.

3 d recombinant IFN-alpha for the treatment of chronic viral hepatitis.

4 ion of immune responses to viral antigens in chronic viral hepatitis.

5 apeutic targets for this most severe form of chronic viral hepatitis.

6 .9%-100%) to those from source patients with chronic viral hepatitis.

7 is would have great therapeutic potential in chronic viral hepatitis.

8 mage from a combination of alcohol abuse and chronic viral hepatitis.

9 ciated with more aggressive liver disease in chronic viral hepatitis.

10 o the cause and clinical course of acute and chronic viral hepatitis.

11 tly increased in humans and chimpanzees with chronic viral hepatitis.

12 irrhosis, primary sclerosing cholangitis, or chronic viral hepatitis.

13 ring the same period, but had no evidence of chronic viral hepatitis.

14 ive agents in renal transplant patients with chronic viral hepatitis.

15 various SL metabolites in 406 patients with chronic viral hepatitis, 203 infected with genotype 1 he

16 was significantly greater among persons with chronic viral hepatitis (69% of cases) and those prescri

17 Chronic viral hepatitis accounts for >80% of liver-relat

18 ng 186,395 patients hospitalized with either chronic viral hepatitis, alcoholism, cirrhosis, or any c

19 isk of hepatocellular carcinoma was 34.4 for chronic viral hepatitis alone, 2.4 for alcoholism alone,

20 Chronic viral hepatitis and alcohol remain leading cause

21 rospective study has analyzed simultaneously chronic viral hepatitis and alcoholism as risk factors f

22 isk of hepatocellular carcinoma was 27.3 for chronic viral hepatitis and alcoholism, 118.5 for chroni

23 etrospective analysis of 1,117 patients with chronic viral hepatitis and analyzed whether age, sex, r

24 ating several clinical conditions, including chronic viral hepatitis and chronic myeloproliferative a

25 ic viral hepatitis and alcoholism, 118.5 for chronic viral hepatitis and cirrhosis, 22.4 for alcoholi

26 FN-alpha is widely used for the treatment of chronic viral hepatitis and malignancies.

27 This finding has important implications for chronic viral hepatitis and other chronic progressive vi

28 Individuals with chronic viral hepatitis and other forms of liver disease

29 s and the morbidity and mortality related to chronic viral hepatitis and released its findings in a r

30 of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty l

31 erythematosus, in 15 (20%) of patients with chronic viral hepatitis, and in four (17%) of those with

32 erythematosus, 14 (50%) of 28 patients with chronic viral hepatitis, and nine (39%) of 23 patients w

33 C diseases, such as alcoholic liver disease, chronic viral hepatitis, and porphyria cutanea tarda.

34 he prognosis and management of patients with chronic viral hepatitis B and C depend on the amount and

35 definition of "normal liver function tests." Chronic viral hepatitis B and C remain important risk fa

36 nvasive methods used to manage patients with chronic viral hepatitis B or C infection.

37 hepatocellular carcinoma among patients with chronic viral hepatitis been prospectively evaluated in

38 hepatocellular carcinoma among patients with chronic viral hepatitis, but it is not a prerequisite fo

39 landscape of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decisio

40 examined operational interventions along the chronic viral hepatitis care continuum, published in Eng

41 y improve engagement and retention along the chronic viral hepatitis care continuum.

42 During development of chronic viral hepatitis, CCL5 and CXCL10 regulate the cy

43 Chronic viral hepatitis depends on the inability of the

44 hepatitis is an uncommon but severe form of chronic viral hepatitis for which there is currently no

45 Chronic viral hepatitis frequently goes undetected until

46 on, nonalcoholic fatty liver disease, and/or chronic viral hepatitis (hepatitis B and C), results in

47 Chronic viral hepatitis (hepatitis B and hepatitis C) in

48 s in the control group was alcohol in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis i

49 hat IL-29 may have therapeutic value against chronic viral hepatitis in human patients.

50 ive virus leading to the most severe form of chronic viral hepatitis in man.

51 was created to assess the clinical impact of chronic viral hepatitis in the United States.

52 Our data suggest that chronic viral hepatitis is associated with a significant

53 The optimal management of chronic viral hepatitis is evolving rapidly.

54 ver failure, and the presence of co-existing chronic viral hepatitis may increase its severity.

55 and EDN (P <.02) compared with patients with chronic viral hepatitis (n = 22), autoimmune hepatitis (

56 To assess the impact of chronic viral hepatitis on host immune response, we anal

57 >/=6 months while receiving ART, and without chronic viral hepatitis or other known causes of chronic

58 hlight the substantial US health burden from chronic viral hepatitis, particularly among persons born

59 In patients with chronic viral hepatitis, probable cirrhosis developed in

60 relevant to the observation that fibrosis in chronic viral hepatitis progresses less rapidly and that

61 sCD163 levels are increased in patients with chronic viral hepatitis, reflecting macrophage activatio

62 nalysed operational interventions to enhance chronic viral hepatitis testing, linkage to care, treatm

63 oth biochemical and histological evidence of chronic viral hepatitis, the extent of liver injury was

64 otoxicity may be more common in persons with chronic viral hepatitis, these data do not support withh